Stock AYTU AYTU BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Aytu BioPharma, Inc.

Equities

AYTU

US0547548588

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
2.84 USD +1.43% Intraday chart for Aytu BioPharma, Inc. +1.79% 0.00%
Feb. 14 Transcript : Aytu BioPharma, Inc., Q2 2024 Earnings Call, Feb 14, 2024
Feb. 14 Earnings Flash (AYTU) AYTU BIOPHARMA Reports Q2 Revenue $22.9M, vs. Street Est of $21.75M MT

Evolution of the average Target Price on Aytu BioPharma, Inc.

Price target over the last 5 years

History of analyst recommendation changes

586274e767d920fa61eeb.VE8gkp11bIv_ixz-VwrWXnqM4TcunVuctGdKf3ztnK0.Gi5Upd4MWt6T0UmUBD7vbwnCgl57_BPk-l8FPg2585s6I2mn0xRf77LOew~eeff16440a34612762bd8c347168ae52

Analyst Recommendations on Aytu BioPharma, Inc.

Maxim Starts Aytu BioPharma at Buy With $5 Price Target MT
HC Wainwright Adjusts Price Target on Aytu BioPharma to $6 From $11, Reiterates Buy Rating MT
Cantor Fitzgerald Lowers Aytu BioPharma's Price Target to $5 From $11, Maintains Overweight Rating MT
HC Wainwright Adjusts Aytu BioScience's Price Target to $11 from $24, Keeps Buy Rating MT
AYTU BIOPHARMA : Cantor Fitzgerald Starts Aytu BioPharma at Overweight With $11 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.84 USD
Average target price
8 USD
Spread / Average Target
+181.69%
High Price Target
8 USD
Spread / Highest target
+181.69%
Low Price Target
8 USD
Spread / Lowest Target
+181.69%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Aytu BioPharma, Inc.

Maxim
HC Wainwright
Cantor Fitzgerald

Ratings for Aytu BioPharma, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. AYTU Stock
  4. Consensus Aytu BioPharma, Inc.